Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Targeting intracelular RANKL in breast cancer

Objective

Breast cancer is the most common malignancy among females in the western world, resulting in half a million deaths annually, mainly due to metastatic disease. Triple negative breast cancer (TNBC) accounts for 1520% of all breast cancers (300.000 women diagnosed worldwide per year). Despite novel treatments, TNBC remains a clinical challenge due to high rate of relapse, a propensity to form visceral metastasis and its heterogeneity. There is an urgent need to identify novel targeted therapies and associated biomarkers for the treatment of the TNBC. IntraRANKL is based on the generation of innovative drugs targeting RANKL for the treatment of TNBC, with a different mechanism of action than denosumab, the gold standard treatment against RANKL.
Small molecule inhibitors generated in IntraRANKL could plausibly be positioned as a novel targeted therapy for TNBC. The main benefits of IntraRANKL are based on the unmet need to improve the treatment of TNBC patients, and the economic burden for public health systems generated by standard non-selected and ineffective cancer treatments. Although our drugs are aimed for TNBC, they can benefit other breast cancer subtypes and tumors expressing RANKL. Moreover, if drugs against RANKL prove to be efficient, they could also clinically benefit patients suffering bone metastasis that are currently treated with denosumab and bisphosphonates. Analyses of RANKL will allow to stratify patients that might benefit from IntraRANKL inhibitors, improving the existing treatments for skeletal-related events and reducing the main complications associated with lifealtering morbidity affecting several types of prevalent cancers.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 150 000,00
Address
C MELCHOR FERNANDEZ ALMAGRO 3
28029 Madrid
Spain

See on map

Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Beneficiaries (1)

My booklet 0 0